Encapsulation of Asparaginase as a Promising Strategy to Improve In Vivo Drug Performance

Asparaginase (ASNase) is a widely applied chemotherapeutic drug that is used to treat Acute Lymphoblastic Leukemia (ALL); however, immune responses and silent inactivation of the drug often limit its bioavailability. Many strategies have been proposed to overcome these drawbacks, including the devel...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Francisca Villanueva-Flores, Andrés Zárate-Romero, Alfredo G. Torres, Alejandro Huerta-Saquero
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	asparaginase acute lymphoblastic leukemia biobetter quality by design nanocarrier Pharmacy and materia medica RS1-441
Acceso en línea:	https://doaj.org/article/ea8024f47a864400801b0a6f7d3cc928
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ea8024f47a864400801b0a6f7d3cc928
record_format	dspace
spelling	oai:doaj.org-article:ea8024f47a864400801b0a6f7d3cc9282021-11-25T18:42:25ZEncapsulation of Asparaginase as a Promising Strategy to Improve In Vivo Drug Performance10.3390/pharmaceutics131119651999-4923https://doaj.org/article/ea8024f47a864400801b0a6f7d3cc9282021-11-01T00:00:00Zhttps://www.mdpi.com/1999-4923/13/11/1965https://doaj.org/toc/1999-4923Asparaginase (ASNase) is a widely applied chemotherapeutic drug that is used to treat Acute Lymphoblastic Leukemia (ALL); however, immune responses and silent inactivation of the drug often limit its bioavailability. Many strategies have been proposed to overcome these drawbacks, including the development of improved formulations (biobetters), but only two of them are currently on the market. Nano- and micro-encapsulation are some of the most promising and novel approaches to enhance in vivo performance of ASNase, preventing the direct contact of the enzyme with the environment, protecting it from protease degradation, increasing the enzymes catalytic half-life, and in some cases, reducing immunogenicity. This review summarizes the strategies, particularly for ASNase nano- and micro-encapsulation, and their main findings, constraints, and current gaps in the state-of-the-art knowledge. The pros and cons of the use of different nanocarriers are discussed with the idea to ultimately provide safer and more effective treatments for patients with ALL.Francisca Villanueva-FloresAndrés Zárate-RomeroAlfredo G. TorresAlejandro Huerta-SaqueroMDPI AGarticleasparaginaseacute lymphoblastic leukemiabiobetterquality by designnanocarrierPharmacy and materia medicaRS1-441ENPharmaceutics, Vol 13, Iss 1965, p 1965 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	asparaginase acute lymphoblastic leukemia biobetter quality by design nanocarrier Pharmacy and materia medica RS1-441
spellingShingle	asparaginase acute lymphoblastic leukemia biobetter quality by design nanocarrier Pharmacy and materia medica RS1-441 Francisca Villanueva-Flores Andrés Zárate-Romero Alfredo G. Torres Alejandro Huerta-Saquero Encapsulation of Asparaginase as a Promising Strategy to Improve In Vivo Drug Performance
description	Asparaginase (ASNase) is a widely applied chemotherapeutic drug that is used to treat Acute Lymphoblastic Leukemia (ALL); however, immune responses and silent inactivation of the drug often limit its bioavailability. Many strategies have been proposed to overcome these drawbacks, including the development of improved formulations (biobetters), but only two of them are currently on the market. Nano- and micro-encapsulation are some of the most promising and novel approaches to enhance in vivo performance of ASNase, preventing the direct contact of the enzyme with the environment, protecting it from protease degradation, increasing the enzymes catalytic half-life, and in some cases, reducing immunogenicity. This review summarizes the strategies, particularly for ASNase nano- and micro-encapsulation, and their main findings, constraints, and current gaps in the state-of-the-art knowledge. The pros and cons of the use of different nanocarriers are discussed with the idea to ultimately provide safer and more effective treatments for patients with ALL.
format	article
author	Francisca Villanueva-Flores Andrés Zárate-Romero Alfredo G. Torres Alejandro Huerta-Saquero
author_facet	Francisca Villanueva-Flores Andrés Zárate-Romero Alfredo G. Torres Alejandro Huerta-Saquero
author_sort	Francisca Villanueva-Flores
title	Encapsulation of Asparaginase as a Promising Strategy to Improve In Vivo Drug Performance
title_short	Encapsulation of Asparaginase as a Promising Strategy to Improve In Vivo Drug Performance
title_full	Encapsulation of Asparaginase as a Promising Strategy to Improve In Vivo Drug Performance
title_fullStr	Encapsulation of Asparaginase as a Promising Strategy to Improve In Vivo Drug Performance
title_full_unstemmed	Encapsulation of Asparaginase as a Promising Strategy to Improve In Vivo Drug Performance
title_sort	encapsulation of asparaginase as a promising strategy to improve in vivo drug performance
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/ea8024f47a864400801b0a6f7d3cc928
work_keys_str_mv	AT franciscavillanuevaflores encapsulationofasparaginaseasapromisingstrategytoimproveinvivodrugperformance AT andreszarateromero encapsulationofasparaginaseasapromisingstrategytoimproveinvivodrugperformance AT alfredogtorres encapsulationofasparaginaseasapromisingstrategytoimproveinvivodrugperformance AT alejandrohuertasaquero encapsulationofasparaginaseasapromisingstrategytoimproveinvivodrugperformance
_version_	1718410807374512128

Encapsulation of Asparaginase as a Promising Strategy to Improve In Vivo Drug Performance

Ejemplares similares